RESEARCH

Open Access

HPyV6 and HPyV7 in urine from immunocompromised patients

Carla Prezioso1,2, Marijke Van Ghelu3,4, Ugo Moens5 and Valeria Pietropaolo1*

Abstract

Background: Human polyomavirus 6 (HPyV6) and HPyV7 are two of the novel polyomaviruses that were originally detected in non-diseased skin. Serological studies have shown that these viruses are ubiquitous in the healthy adult population with seroprevalence up to 88% for HPyV6 and 72% for HPyV7. Both viruses are associated with pruritic skin eruption in immunocompromised patients, but a role with other diseases in immunoincompetent patients or malignancies has not been established.

Methods: PCR was used to determine the presence of HPyV6 and HPyV7 DNA in urine samples from systemic lupus erythematosus (n = 73), multiple sclerosis (n = 50), psoriasis vulgaris (n = 15), arthritic psoriasis (n = 15) and HIV-positive patients (n = 66). In addition, urine from pregnant women (n = 47) and healthy blood donors (n = 20) was investigated.

Results: HPyV6 DNA was detected in 21 (28.8%) of the urine specimens from SLE patients, in 6 (9.1%) of the urine samples from the HIV-positive cohort, and in 19 (40.4%) samples from pregnant women. HPyV7 DNA was only found in 6 (8.2%) of the urine specimens from SLE patients and in 4 (8.5%) samples from pregnant women. No HPyV6 and HPyV7 viruria was detected in the urine samples from the other patients.

Conclusions: HPyV6, and to a lesser extend HPyV7, viruria seems to be common in SLE and HIV-positive patients, and pregnant women. Whether these viruses are of clinical relevance in these patients is not known.

Keywords: Blood donor, HIV, Human polyomaviruses, Immunocompromised, Multiple sclerosis, PCR, Pregnant women, Psoriasis, Viruria

Background

A virus was isolated in the 1950ies from mouse and because of its ability to induce multiple tumors in animal models named polyomavirus (PyV) [1]. Since then, PyVs have been described in other mammals, including humans, birds, and fish [2, 3]. Members of the Polyomaviridae family are characterized by non-enveloped virus particles containing a circular double-stranded DNA genome of approximately 5000 base-pairs (bp). A typical PyV genome codes for the regulatory proteins large T-antigen (LT) and small T-antigen (sT) and at least two capsid proteins, VP1 and VP2. The T-antigens are expressed early during the infection cycle, and are required for viral transcription and replication [4]. These proteins possess oncogenic properties [5–7]. The capsid proteins are expressed after viral replication has initiated and therefore later during infection of the host cell. A non-coding region (NCCR), which encompasses the origin of replication and the transcription regulatory sequences for both the T-antigens and the VPs, separates the coding regions for the T-antigens and capsid proteins [4].

So far, 15 polyomavirus genomes have been isolated from humans. In 1971, BKPyV and JCPyV were the first...
human PyVs to be described in literature. They were isolated from urine of a renal transplant patient and the brain from a patient with progressive multifocal encephalopathy (PML), respectively [8, 9]. Since then, novel PyVs were originally described in nasopharyngeal aspirates (KIPyV; [10]), bronchoalveolar lavage (WUPyV; [11]), Merkel cell carcinoma (MCPyV; [12]), skin (HPyV6, HPyV7, TSPyV, LIPyV; [13–15]), serum (HPyV9; [16]), genital warts (HPyV10; [17]), feces (STLPyV, QPyV; [18, 19]), liver (HPyV12; [20]), and muscle (NJPyV; [21]). Although HPyVs seem to establish a harmless persistent infection in healthy individuals [22, 23], they may cause diseases in immunocompromised patients. BKPyV is associated with nephropathy in renal transplant recipients and hemorrhagic cystitis in hematopoietic stem cell transplantation [24, 25]. ICPyV causes PML and few cases of JCPyV-associated nephropathy in renal transplant patients have been observed [26–28]. MCPyV is the cause of Merkel cell carcinoma, a neuroendocrine skin cancer [12], and TSPyV is the etiological factor of trichodysplasia spinulosa in immunodeficient patients [29].

Serological studies have demonstrated that HPyV6 and HPyV7 infections are ubiquitous in the healthy adult human population, with a seroprevalence ranging between 74 and 93% for HPyV6 and between 56 and 80% for HPyV7 [30–34]. The presence of HPyV6 and HPyV7 DNA has been examined in different biological samples of healthy controls and different patient groups in a quest to determine the cell tropism and the possible association of these viruses with diseases. HPyV6 and HPyV7 are natural inhabitants of the healthy skin virome [13, 35–39]. These viruses have been detected in other specimens. HPyV6 was present in the urine from one out of 70 patients with hemorrhagic cystitis [40], and HPyV7 was found in urine from one out of 100 liver transplant patients [41] and from five out of 43 hematopoietic stem cell transplant patients [40]. HPyV6, but not HPyV7, was detected in cerebrospinal fluid (CSF) from one out of 243 neurological patients [42] and from one HIV-positive patient with JCpyV-negative progressive multifocal leukoencephalopathy [43]. HPyV6 DNA could be amplified from two out 110 serum samples from HIV-negative patients [44], and from nasopharyngeal aspirates [45] and lymph nodes [46]. HPyV7 DNA was present in the blood from a patient with dyskeratotic dermatosis [47]. Both viruses are also present in eyebrow hair from healthy men [38], and in cervical specimens of women [48].

Clear associations with diseases have not been established, except in severely immunocompromised patients, where HPyV6 and HPyV7 can cause pruritic dermatoses characterized by hyperproliferation of dyskeratotic (with prematurity or altered differentiation) keratinocytes that result in brownish skin plaques [49–53]. The presence of HPyV6 has sporadically been detected in the skin from lichen simplex chronicus, eosinophilic pustular folliculitis and suppurative folliculitis patients [39, 54]. HPyV6 has also been associated with Kimura disease and patients with dermatopathic lymphadenitis [46, 55]. HPyV6, but not HPyV7 DNA was present in anal/rectal swabs of some men who had sex with men that were HIV-negative, but neither HPyV6 nor HPyV7 were detected in throat/oral swabs and in urethral specimens from these subjects [56].

A role for HPyV6 and HPyV7 in human cancers is lacking although low viral genome copy numbers have been found in few samples of different tumor tissue types [39, 44, 57–69].

To further exploit a possible causative role of HPyV6 and HPyV7 in immunocompromised patients, we examined the presence of DNA from these viruses in urine from systemic lupus erythematosus (SLE), HIV positive, psoriasis, and multiple sclerosis patients, as well as in urine from pregnant women and healthy blood donors. HPyV6 viruria was found in SLE patients, HIV-positive patients and pregnant women, whereas HPyV7 DNA was only detected in SLE and HIV-positive patients. The prevalence of HPyV6 was higher than HPyV7 in these two patient groups. Longitudinal study of the SLE patients showed intermittent viruria.

Methods
Patients’ samples
Archival urine samples from five anonymous SLE patients (four women and one man) from Stavanger (Norway) were used. These samples were acquired over a 1-year period. In total, 73 samples were collected [70]. Forty-seven single archival urine specimens from healthy women who were 18–39 weeks pregnant, collected at the university hospital of Northern Norway, have been previously described [70]. The urine samples were stored as 1 ml aliquots in a −20 °C freezer that was only used for storage of samples. The freezer stands in a different room separated from the lab, PCR room and post PCR room. The urine samples from SLE patients and from pregnant women were kept in separate drawers in the −20 °C freezer. The study was approved by the Regional Committees for Medical and Health Research Ethics (REK; reference number 2012/420). Fifty urine samples were obtained from a cohort of 30 relapsing remitting multiple sclerosis (RRMS) subjects, followed up at the Department of Human Neurosciences of Sapienza University of Rome and recruited between March 2016 and March 2018. All participants fulfilled the Italian Agency of Drug (AIFA) criteria for natalizumab treatment and the therapeutic protocol consisted of administration of 300 mg
intravenous natalizumab every 4 weeks. The enrolled patients (12 males/18 females, mean age ± stand. dev. 30.2 ± 6.6; mean months of illness ± stand. dev. 85 ± 85.5; mean Expanded Disability Status Scale (EDSS) ± stand. dev. 1.9 ± 1.3) were visited before natalizumab treatment (baseline: 0 infusions) and after infusions at weeks 4, 8, 12, 16 and 20. Patients signed informed consent based on the approved Ethic Committee of Policlinico Umberto I of Rome (protocol number 130/13). Sixty-six urine specimens were collected from a cohort of 66 HIV-1-positive patients, admitted to the Infectious Diseases Clinic of the Polyclinic Tor Vergata Foundation from January 2019 to December 2019. Among the enrolled patients (55 males/11 females, age ranged from 21 to 76 years old; mean age ± stand. dev. 40.5 years old; median: 39.9 years old) 22 were new diagnoses naive to treatment and 44 were experienced patients on treatment with a triple-based antiretroviral regimen including protease/reverse transcriptase/integrase inhibitors. The study was approved by the local Ethic Committee of the University Hospital Tor Vergata (Rome, Italy) (protocol number 0027234/2018, 19 December 2018), and patients informed consent was ascertained. Healthy donors (n=20), aged 18±63 years, were recruited from blood donors attending the Italian Red Cross Blood Transfusion Centre in Rome (RMTIC) and a sample of urine was obtained. Thirty urine specimens were collected from a cohort of 30 psoriasis patients, of both genders with a mean age of 33±4 years, referred to the Dermatology Institute IDI IRCSS of Rome. One group of subjects, consisting of 15 patients, diagnosed with psoriasis vulgaris and the another 15 patients were diagnosed with psoriatic arthritis. These subjects did not show other autoimmune and chronic diseases. Informed consent was obtained from all patients.

DNA purification and PCR
DNA was purified from 200 µl urine samples. The samples were centrifuged for 1 min at 12,000 g to remove cell debris. DNA purification was performed on cell-cleared urine using the QIAamp MinElute Virus Spin Kit according to the manufacturer’s instructions (Qiagen, Hilden, Germany; cat. No. 57704). DNA was eluted in 50 µl and used in PCR. The following primers were used to amplify a 299 bp fragment of LT: HPyV6LT.F: CAA TGATACATACCTGGAC (nucleotides 4316-4335 in isolate 601a; HM011558) and HPyV6LT.R: GAT TTC CGT TTG TG (nucleotides 4591-4610 in isolate 713a; HM011586). The PCR conditions were 40 cycles of 30 s at 90 °C, 30 s at 55 °C, and 1 min at 72 °C. PCR was performed with Accustart II PCR SuperMix (Qunatabio, Beverly, MA, USA; cat. no. 95137-500). The plasmids pHPyV6-607a (Addgene, Watertown, MA, USA; cat. no. 24727) and pHPyV7-713a (Addgene; cat. no. 24728) were used as positive controls and to test the sensitivity of our PCR.

Statistical analysis
HPyV6 and HPyV7 detection were summarized by counts and proportions. If continuous variables were normally distributed, they were expressed as mean ± SD; if not, they were expressed by median and range. The χ² test was performed to evaluate differences in the viral detection and the Mann–Whitney U-test for non-normally distributed continuous variables was applied to analyse differences between patients. A p value < 0.05 was considered statistically significant.

Results
To investigate whether other immunocompromised conditions may lead to viruria of HPyV6 and HPyV7, urine specimens of five cohorts were examined for the presence of DNA of these viruses. The cohorts included: systemic lupus erythematosus (SLE) patients, multiple sclerosis patients, HIV-positive patients, psoriasis patients and pregnant women. HPyV6 DNA was detected in 28.8% of the urine specimens from SLE patients and in 40.4% of the samples from pregnant women (Table 1). No HPyV6

| Table 1 DNA prevalence of HPyV6 and HPyV7 in different patient groups |
|---------------------------------|----------------------------|-----------------
| Patient group (n)              | HPyV6 (%)                  | HPyV7 (%) |
|--------------------------------|----------------------------|-----------|
| SLE (5)                        |                            |           |
| SLE1 (5 samples)               | 1 (20.0)                   | 0 (0)     |
| SLE2 (7 samples)               | 1 (14.3)                   | 0 (0)     |
| SLE3 (13 samples)              | 4 (30.8)                   | 2 (15.4)  |
| SLE4 (16 samples)              | 4 (25.0)                   | 3 (18.8)  |
| SLE5 (32 samples)              | 11 (34.4)                  | 1 (3.1)   |
| Total samples (73)             | 21 (28.8)                  | 6 (8.2)   |
| Multiple sclerosis (30)        | 0 (0)                      | 0 (0)     |
| Psoriasis vulgaris (15)        | 0 (0)                      | 0 (0)     |
| Arthritic psoriasis (15)       | 0 (0)                      | 0 (0)     |
| HIV-positive (66)              | 6 (9.1)                    | 0 (0)     |
| Pregnant women (47)            | 19 (40.4)                  | 4 (8.5)   |
| Blood donors (20)              | 0 (0)                      | 0 (0)     |

* These samples were also HPyV6 positive
b One sample was also HPyV6 positive
c This sample was also HPyV6 positive
d Two samples were also positive for HPyV6
could be amplified in urine from multiple sclerosis and psoriasis patients and from healthy blood donors. HPyV7 DNA was only detected in urine from SLE and pregnant women, although with a lower prevalence than HPyV6 (8.2% and 8.5%, respectively). The HPyV7-positive urine samples from SLE patient 3 were also HPyV6 positive. Two unique urine samples from SLE patient 4 and patient 5 contained both HPyV6 and HPyV7. Of the four HPyV7 positive urine samples from pregnant women, two were also positive for HPyV6. Six of the HIV-positive patients had HPyV6 viruria, but none had HPyV7 viruria. Interestingly, the six HIV patients with a HPyV6 positive urine sample were naïve, i.e., they had just started HAART treatment. HPyV6 and HPyV7 were not detected in any of the urine specimens from healthy blood donors, multiple sclerosis patients and psoriasis patients. No significant association was found between the presence of HPyV6 and HPyV7 DNA versus age and gender when applicable, and HPyV6 and HPyV7 DNA versus disease ($p < 0.05$).

**Discussion**

HPyV6 and HPyV7 DNA has been detected in different body samples of immunocompromised patients [39, 43, 49–53], but viruria of these viruses has not been examined in SLE and MS patients in pregnant women. We found that DNA of both viruses was detected in the urine from some SLE patient and pregnant women, with a higher prevalence of HPyV6 compared to HPyV7. A previous study failed to detect HPyV6 and HPyV7 DNA in skin from two SLE patients [39]. Similar to HPyV6 and HPyV7, intermittent episodes of urine shedding of BKPyV and JCPyV and simultaneous viruria of BKPyV and JCPyV was observed in SLE patients [70–75].

We could not detect HPyV6 or HPyV7 urine shedding in MS patients treated with natalizumab. CSF from 10 MS patients were negative for HPyV6 and HPyV7 DNA [42], suggesting that reactivation of these two HPyVs may be a rare event in MS patients. Studies by several groups have shown that BKPyV, JCPyV or both can be detected in urine from MS patients receiving natalizumab or β-interferon [76–81], indicating that HPyV viruria is not uncommon in these patients.

We did not discover HPyV6 and HPyV7 DNA in the urine samples of healthy blood donors. This is in agreement with a previous study that also failed to detect HPyV6 in the urine from 50 healthy volunteers [82] or in 189 urine specimens from symptomatic children and adults undergoing routine diagnostic testing [83]. A longitudinal study on 169 urine samples obtained from 32 organ transplant patients showed only one urine sample positive for HPyV7 DNA. This sample was obtained from a liver transplant child 8 months after transplantation [41].

The presence of HPyV6, but not HPyV7 DNA has been described in CSF, serum, and anal/rectal swabs from HIV-positive individuals [42, 43, 56], but neither HPyV6 nor HPyV7 were found in urethral samples or urine [56, 84]. We found that 6 of our 66 HIV-positive subjects displayed HPyV6 viruria, whereas Torres et al., examined only 19 urine samples [84]. The relative small number of subjects in the latter study may explain the different findings with our results.

Hashida and colleagues examined nonlesional and lesional skin swabs from 30 psoriasis patients and reported that 58% (nonlesional) and 54% (lesional) samples were HPyV6 positive, while the HPyV7 prevalence was 42% and 25%. Of the skin swabs from healthy individuals, 14% were positive for HPyV6 and 6% were positive for HPyV7. The viral loads were also higher in both nonlesional and lesional samples of the psoriasis patients compared to the healthy individuals, indicating that HPyV6 and HPyV7 infection is higher in this inflammatory skin condition [85].

While PCR-based studies have shown that BKPyV and JCPyV viruria is common in pregnant women [86–89], less is known about urinal excretion of the novel HPyV. Cosma et al. [90] examine KIPyV, WUPyV and HPyV9 viruria in 100 non-pregnant and 100 pregnant women and found HPyV9 viruria in 2 non-pregnant and 3 pregnant women, whereas no KIPyV and WUPyV was detected in either cohorts. To the best of our knowledge, HPyV6 and HPyV7 viruria has not been investigated in pregnant women. We found that 40.4% of the women were positive for HPyV6 and 8.5% were positive for HPyV7. Two of the women (4.3%) had a urine sample that contained DNA of both viruses.

**Conclusions**

In conclusion, immunodeficient conditions in SLE and HIV-positive patients may lead to viruria of HPyV6 and HPyV7, but whether these observations are linked to clinical conditions remain to be further explored. Our longitudinal study on SLE patients show that some of these patients may have intermitted episodes of HPyV6/7 reactivation.

**Abbreviations**

CSF: cerebrospinal fluid; HPyV: human polyomavirus; MS: multiple sclerosis; VP: viral protein; SLE: systemic lupus erythematosus.

**Acknowledgements**

The APC was funded by UiT, The Arctic University of Norway.

**Authors’ contributions**

Conceptualization: UM and VP; methodology: CP, MVG, UM, VP; experiments: CP, MVG, UM; validation and formal analysis: CP, MVG, UM, VP; original draft preparation: UM and VP; writing, reviewing and editing the manuscript: CP, MVG, UM and VP. All authors read and approved the final manuscript.
Funding
This work was supported by the Aaker Foundation (A65285;UM) and Carla Prezioso was supported by the Italian Ministry of Health (starting Grant: SG-2018-12366194).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Ethical approval and consent to participate
This study was approved by the Regional Committees for Medical and Health Research Ethics, University of Tromsø—The Arctic University of Norway (REK; reference number 2012/420).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Rome, Italy. 2 Microbiology of Chronic Neuro-Degenerative Pathologies, IRCCS San Raffaele Pisana, Rome, Italy. 3 Department of Medical Genetics, Division of Child and Adolescent Health, University Hospital of North Norway, Tromsø, Norway. 4 Department of Clinical Medicine Faculty of Health Sciences, University of Tromsø - The Arctic University of Norway, Tromsø, Norway. 5 Department of Medical Biology, Faculty of Health Sciences, University of Tromsø - The Arctic University of Norway, Tromsø, Norway.

Received: 3 December 2020 Accepted: 12 January 2021
Published online: 22 January 2021

References
1. Gross L. A filterable agent, recovered from Ak leukemic extracts, caus- ing salivary gland carcinomas in C3H mice. Proc Soc Exp Biol Med. 1953;83:414–21.
2. Buck CB, Van Doorslaer K, Peretti A, Geoghegan EM, Tisza MJ, An P , Katz JP , Pipas JM, McBride AA, Camus AC, et al. The ancient evolutionary history of polyomaviruses. PLoS Pathog. 2016;12:e1005574.
3. Calvignac-Spencer S, Feltkamp MC, Daugherty MD, Moens U, Ramqvist T, Johne R, Ehlers B. A taxonomy update for the family Polyomaviridae. Arch Virol. 2016;161:1739–50.
4. Moens U, Krumbholz A, Ehlers B, Zell R, Johne R, Calvignac-Spencer S, Lauber C. Biology, evolution, and medical importance of polyomaviruses: an update. Infect Genet Evol. 2017;54:18–38.
5. Moens U, Van Ghelue M, Johannessen M. Oncogenic potentials of the human polyomavirus regulatory proteins. Cell Mol Life Sci. 2007;64:1656–78.
6. Topalis D, Andrei G, Snoeck R. The large tumor antigen: a “Swiss Army knife” protein possessing the functions required for the polyomavirus life cycle. Antivir Res. 2013;97:122–36.
7. Baez CF, Brandão Varella R, Villani S, Delbue S. Human polyomaviruses: the battle of large and small tumor antigens. Virology (Auckl). 2017;8:1172–1747875.
8. Padgett BL, Walker DL, ZuRhein GM, Ecco Rae RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet. 1971;1:1257–60.
9. Gardner SD, Field AM, Coleman DW, Hulme B. New human papova- virus (B.K) isolated from urine after renal transplantation. Lancet. 1971;1:1253–7.
10. Allander T, Andreasson K, Gupta S, Bjerkner A, Bogdanovic G, Persson MA, Dalanis T, Ramqvist T, Andersson B. Identification of a third human polyomavirus. J Virol. 2007;81:4130–6.
11. Gaynor AM, Nissen MD, Whitey DM, Mackay IM, Lambert SB, Wu G, Brennan DC, Storch GA, Sloots TP, Wang D. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog. 2007;3:e64.
12. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavi- rus in human Merkel cell carcinoma. Science. 2008;319:1096–100.
13. Schowalter RM, Pastrana DV, Pumphrey KA, Moyer AL, Buck CB. Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. Cell Host Microbe. 2010;7:509–15.
14. van der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN, Gor- balenya AE, Feltkamp MC. Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient. PLoS Pathog. 2010;6:e1001024.
15. Ghet T, Dutta S, Oliver J, Robitaille A, Hampras S, Combès JD, McKay- Chapin S, Le Calvez-Kelm F, Fenske N, Chengelis B, et al. Isolation and characterization of a novel putative human polyomavirus. Virology. 2017;506:45–54.
16. Scuda N, Hofmann J, Calvignac-Spencer S, Ruprecht K, Liman P, Kühn J, Hengel H, Ehlers B. A novel human polyomavirus closely related to the african green monkey-derived lymphotropic polyomavirus. J Virol. 2011;85:4856–89.
17. Buck CB, Phan GQ, Rajji MT, Murphy PM, McDermott DH, McBride AA. Complete genome sequence of a tenth human polyomavirus. J Virol. 2012;86:10887.
18. Lim ES, Reyes A, Antonio M, Saha D, Ikumapayi UN, Adevyemi M, Stine OC, Skelton R, Brennan DC, Mlakosays KS, et al. Discovery of STL polyomavirus, a polyomavirus of ancestral recombinant origin that encodes a unique T antigen. J virology. 2013;87:295–303.
19. Ondov BD, Starrett GJ, Sappington A, Kostic A, Koren S, Buck CB, Phillips AM. Mask Screen: high-throughput sequence containment estimation for genome discovery. Genome Biol. 2019;20:232.
20. Korup S, Rietseh J, Calvignac-Spencer S, Trusch F, Hofmann J, Moens U, Sauer I, Voigt S, Schmuck R, Ehlers B. Identification of a novel human poly- omavirus in organs of the gastrointestinal tract. PLoS ONE. 2013;8:e58021.
21. Mishra N, Pereira M, Rhodes RH, An P P, Pipas JM, Jain K, Kapoor A, Briese T, Faust PL, Lipkin W. Identification of a novel polyomavirus in a pancreatic transplant recipient with retinal blindness and vasculitic myopathy. J Infect Dis. 2014;210:1595–9.
22. Deoerries K. Human polyomavirus JC and BK persistent infection. Adv Exp Med Biol. 2006;577:102–16.
23. Imperiale MJ, Jiang M. Polyomavirus persistence. Anna Rev Virol. 2016;3:517–32.
24. Leung AY, Yuen KY, Kwong YL. Polyoma BK virus and haemorrhagic cystitis in haemato poetic stem cell transplantation: a changing paradigm. Bone Marrow Transplant. 2005;36:929–37.
25. Ramos E, Drenachenberg CB, Wali R, Hirsch HH. The decade of poly- omavirus BK-associated nephropathy: state of affairs. Transplantation. 2009;87:621–30.
26. Yang D, Keys B, Conti D, Foulele K, Selle recht K, Cook L, Lopez-Soler RI. JC polyomavirus nephropathy, a rare cause of transplant dysfunction: case report and review of literature. Transpl Infect Dis. 2017;19(2):12654.
27. Atkinson AL, Atwood WJ. Fifty years of JC polyomavirus: a brief overview and remaining questions. Viruses. 2020;12:969.
28. Cortese I, Reich DS, Nath A. Progressive multifocal leukoen cephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2020;17(1):37–51.
29. Kazem S, van der Meijden E, Feltkamp MC. The trichodysplasia spinulosa-associated polyomavirus: virological background and clinical implications. APMS. 2013;121:770–2.
30. Nicol JT, Robinot R, Carpenter A, Carandina G, Mazzoni E, Togno- n M, Touze A, Lawyers P, Gaugga M, Coursaget P. Age-specific seroprevalences of merkel cell polyomavirus, human polyomaviruses 6, 7, and 9, and trichodysplasia spinulosa-associated polyomavirus. Clin Vaccine Immunol. 2013;20:263–8.
31. van der Meijden E, Bialasiewicz S, Rockett RJ, Tozer SJ, Sloots TP, Felkamp MC. Different serologic behavior of MCPyV, TSPyV, HPyV6, HPyV7 and HPyV9 polyomaviruses found on the skin. PLoS ONE. 2013;8:e81078.
32. Kobes C, Casabonne D, Benavente Y, Costas L, Gonzalez-Barca E, Aymerich M, Campo E, Tardon A, Jiménez-Moleón JJ, Castaño-Vinyals G, et al. Different serologic behavior of MCPyV, TSPyV, HPyV6, HPyV7 and HPyV9 polyomaviruses in organs of the gastrointestinal tract. PLoS ONE. 2013;8:e58021.
33. Gossai A, Waterboer T, Nelson HH, Michel A, Willhauck-Fleckenstein M, Farzan SF, Hoen AG, Christensen BC, Kelsey KT, Maris CT, et al. Seroepide- miology of human polyomaviruses in a US population. Am J Epidemiol. 2016;183:61–9.
34. Kammenga S, van der Meijden E, Feltkamp MCW, Zaaijer HL. Seroprevalence of fourteen human polyomaviruses determined in blood donors. PLoS ONE. 2018;13(2):e0206273.
35. Fouloungne V, Sauvage V, Hebert C, Dereure O, Cheval J, Gouill MA, Pariente K, Segondy M, Burgués A, Manuguerra JC, et al. Human skin microbiota: high diversity of DNA viruses identified on the human skin by high throughput sequencing. PLoS ONE. 2012;7:e38499.
36. Wieland U, Silling S, Hellmich M, Potthoff A, Pfister H, Kreuter A. Human polyomaviruses 6, 7, 9, 10 and Trichodysplasia spinulosa-associated polyomavirus in HIV-infected men. J Gen Virol. 2014;95:928–32.
37. Wyle KM, Mhindukulasna KA, Zhou Y, Sodergren E, Storch GA, Weinstock GM. Metagenomic analysis of double-stranded DNA viruses in healthy adults. BMC Biol. 2014;12:71.
38. Foulongne V, Sauvage V, Hebert C, Dereure O, Cheval J, Gouilh MA, D’Alessandro S, Campisciano G, Comar M, Ferrante P, et al. Human polyomaviruses in children undergoing transplantation, United States, 2008–2010. Emerg Infect Dis. 2016;20:810–7.
39. Schrama D, Groesser L, Ugur S, Silliker J, Buck CB, Cerroni L, Thelier A, Becker JC. Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations. JAMA Dermatol. 2014;150:1180–6.
40. Frouin E, Guillot B, Larrieux M, Tempier A, Bouille N, Fouloungne V, Girard C, Costes V, Solassol J. Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and PI3KCA pathways but not HPV nor HPyV viral infection. PLoS ONE. 2014;9:e110478.
41. Delbue S, Elia F, Segondy M, Berti S, Marchioni E, Ferrante P, Phan TG, Delwart E. Human polyomavirus 6 DNA in the cerebrospinal fluid of an HIV-positive patient with leukoencephalopathy. J Clin Virol. 2015;68:24–7.
42. Fava P, Merlino C, Novelli M, Ponti R, Galliano I, Montanari P, Tovo PA, Fierro MT, Bergallo M. HPyV6, HPyV7 and TSPyV DNA sequences detection in skin disease patients and healthy subjects. J Eur Acad Dermatol Venereol. 2016;30:624–7.
43. Foulongne V, Sauvage V, Hebert C, Dereure O, Cheval J, Gouilh MA, D’Alessandro S, Campisciano G, Comar M, Ferrante P, et al. Human polyomaviruses in the cerebrospinal fluid of neurological patients. Microorganisms. 2019;7:16.
44. Delbue S, Elia F, Segondy M, Berti S, Marchioni E, Ferrante P, Phan TG, Delwart E. Human polyomavirus 6 DNA in the cerebrospinal fluid of an HIV-positive patient with leukoencephalopathy. J Clin Virol. 2015;68:24–7.
45. Frouin E, Guillot B, Larrieux M, Tempier A, Bouille N, Fouloungne V, Girard C, Costes V, Solassol J. Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and PI3KCA pathways but not HPV nor HPyV viral infection. PLoS ONE. 2014;9:e110478.
46. Beckvordersandforth J, Pujiar S, Rennspuess D, Spiel EJ, Winnepennickx V, Diaz C, Weyers W, Haag A, Kurz AK, Zur HA. Frequent detection of human polyomavirus 6 in keratoacanthomas. Diagn Pathol. 2016;11:58.
47. Bergallo M, Dapra V, Fava P, Ponti R, Calvi C, Montanari P, Novelli M, Quaglini P, Galliano I, Fierro MT. DNA from human polyomaviruses, MWPyV, HPyV6, HPyV7, HPyV9 and HPyV12 in cutaneous T-cell lymphomas. Anticancer Res. 2018;38:4111–4.
48. Purdie KJ, Proby CM, Rizvi H, Griffin H, Doorbar J, Sommerlad M, Feltkamp MT, Bergallo M. Human polyomavirus 6 detected in cases of eosinophilic dermatitis: preliminary findings. Microorganisms. 2015;3:141.
49. Aboudar M, Salmona M, De Masson A, Rivet J, Cardot-Leccia N, Mercier-Delarue S, Ram-Wolff C, Garnier B, Bouazid JD, Lebbé C, et al. Diversity and compartmentalization of human polyomavirus 7 in a patient with dyskeratotic dermatosis. J Eur Acad Dermatol Venereol. 2020;34:e609–12.
50. Colli C, De Seta F, Ferrante P, Comar M. Merkel cell polyomavirus is associated with pruritic and dyskeratotic dermatoses. J Am Acad Dermatol. 2015;72:221–8.
51. Frouin E, Guillot B, Larrieux M, Tempier A, Bouille N, Fouloungne V, Girard C, Costes V, Solassol J. Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and PI3KCA pathways but not HPV nor HPyV viral infection. PLoS ONE. 2014;9:e110478.
52. Beckvordersandforth J, Pujiar S, Rennspuess D, Spiel EJ, Winnepennickx V, Diaz C, Weyers W, Haag A, Kurz AK, Zur HA. Frequent detection of human polyomavirus 6 in keratoacanthomas. Diagn Pathol. 2016;11:58.
53. Schrama D, Groesser L, Ugur S, Silliker J, Buck CB, Cerroni L, Thelier A, Becker JC. Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations. JAMA Dermatol. 2014;150:1180–6.
54. Frouin E, Guillot B, Larrieux M, Tempier A, Bouille N, Fouloungne V, Girard C, Costes V, Solassol J. Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and PI3KCA pathways but not HPV nor HPyV viral infection. PLoS ONE. 2014;9:e110478.
55. Beckvordersandforth J, Pujiar S, Rennspuess D, Spiel EJ, Winnepennickx V, Diaz C, Weyers W, Haag A, Kurz AK, Zur HA. Frequent detection of human polyomavirus 6 in keratoacanthomas. Diagn Pathol. 2016;11:58.
56. Bergallo M, Dapra V, Fava P, Ponti R, Calvi C, Montanari P, Novelli M, Quaglini P, Galliano I, Fierro MT. DNA from human polyomaviruses, MWPyV, HPyV6, HPyV7, HPyV9 and HPyV12 in cutaneous T-cell lymphomas. Anticancer Res. 2018;38:4111–4.
57. Purdie KJ, Proby CM, Rizvi H, Griffin H, Doorbar J, Sommerlad M, Feltkamp MT, Bergallo M. Human polyomavirus 6 detected in cases of eosinophilic dermatitis: preliminary findings. Microorganisms. 2015;3:141.
58. Aboudar M, Salmona M, De Masson A, Rivet J, Cardot-Leccia N, Mercier-Delarue S, Ram-Wolff C, Garnier B, Bouazid JD, Lebbé C, et al. Diversity and compartmentalization of human polyomavirus 7 in a patient with dyskeratotic dermatosis. J Eur Acad Dermatol Venereol. 2020;34:e609–12.
59. Colli C, De Seta F, Ferrante P, Comar M. Merkel cell polyomavirus is associated with pruritic and dyskeratotic dermatoses. J Am Acad Dermatol. 2015;72:221–8.
60. Frouin E, Guillot B, Larrieux M, Tempier A, Bouille N, Fouloungne V, Girard C, Costes V, Solassol J. Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and PI3KCA pathways but not HPV nor HPyV viral infection. PLoS ONE. 2014;9:e110478.
80. Pietropaolo V, Bellizzi A, Anzivino E, Iannetta M, Zingaropoli MA, Rodio DM, Cioccolo S, Scrivo R, Morreale M, Pontecorvo S, Francia A, Vullo V, et al. Human polyomavirus BK replication in the human host. Environ Pollut. 2019;241:234–9.

81. Nali LH, Fink MC, do Olival GS, Moraes L, Callegaro D, Tilbery CP, Vidal JE, Sumita LM, de Oliveira AC, Romano CM. Polyomavirus detection in multiple sclerosis patients under nataluzumab therapy: profile and frequency of urinary shedding. J Med Virol. 2017;89:528–34.

82. Dolci M, Favero C, Bollati V, Campo L, Cattaneo A, Bonzini M, Villani S, Ticozzi R, Ferrante P, Delbue S. Particulate matter exposure increases JC polyomavirus replication in the human host. Environ Pollut. 2018;241:234–9.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.